Penn’s Abramson Cancer Center Presents New Cancer Research at 2022 American Society of Hematology (ASH) Annual Meeting
Researchers from Penn’s Abramson Cancer Center presented the preliminary results of an ongoing Phase I clinical trial for a novel CAR T therapy to be used after cancer.
Neuralert Technologies included in TIME’s List of the Best Inventions
The lightweight, non-invasive wristband device can detect the stroke symptoms in as little as 15 minutes.
Emily Whitehead’s CAR-T Cell Therapy Journey Featured on CBS
CBS This Morning recently featured a story about Emily Whitehead, the first pediatric patient to receive Penn-invented CAR T cell therapy to fight cancer.
Drew Weismann Speaks on the Future of mRNA Technology in Bloomberg’s “The Big Take” Podcast
Weissman talks about his discovery and the impact of mRNA technology on the development of therapies for flu, cancer and rare genetic diseases.
PCI Team Member and Penn Medicine Featured in Washington Post
Carter Caldwell, Director of the Penn Medicine Co-Investment Program, was featured in the Washington Post’s Medical Mysteries column which described his journey following life-changing brain surgery.
Penn Medicine and Candel Therapeutics partner to pursue potential solid tumor CAR-T cell therapy
The University of Pennsylvania’s Center for Cellular Immunotherapies, led by cell therapy pioneer Dr. Carl June, has entered into a cancer treatment collaboration with Candel Therapeutics.
Weissman Lab is Working on New Type of Vaccines to Protect Against All Coronaviruses
The Weissman Lab is working towards developing vaccines that not only target multiple COVID variants, but also multiple types of coronaviruses.
Penn spinout Capstan Therapeutics Launches with Goal of Incorporating mRNA into CAR-T Cell Therapy
This new approach to CAR-T therapy will involve mRNA therapy that directs cells in the body to make proteins to prevent or fight disease.
Tech of the Month: AI-Powered Optical Tool for Fluorescence-Guided Oncological Surgery
This tool provides immediate and accurate tumor identification without the frozen section staining process normally required, saving over 30 minutes and thousands of dollars per tumor per operation.
Jim Wilson Speaks on What’s Next for Cell and Gene Therapy in Philadelphia
On September 8, Jim Wilson, director of Penn Medicine's gene therapy program and director of Penn's orphan disease center. sat down with health care reporter John George for a wide-ranging discussion.